pharma · Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · BCAX
Bicara Therapeutics
Bicara Therapeutics is a pharma organization headquartered in Boston, USA. It trades on NYSE under ticker BCAX. Primary therapeutic focus areas include Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squa
Boston, USA HQ
2020 Founded
115 Employees
Public company Type
BCAX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2020
- Employees
- 115
- Programs
- 6
- Drugs
- 4
- Patents
- 0
Ficerafusp alfa
Phase 2 · small molecule · Squamous Cell Carcinoma of Head and Neck (SCCHN)
Ficerafusp alfa for Squamous Cell Carcinoma of Head and Neck (SCCHN) is a Phase 2 program (small_molecule) at Bicara Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code GORTEC 2025-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bicara Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Squamous Cell Carcinoma of Head and Neck (SCCHN)
- Status
- active
- Trials
- 1